Lerodalcibep, sold under the brand name Lerochol, is a medication used for the treatment for high cholesterol. It is a recombinant fusion protein that contains a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and human serum albumin. Lerodalcibep was approved for medical use in the United States in December 2025.
Medical uses Lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
References
External links Clinical trial number NCT04034485 for "Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH" at ClinicalTrials.gov Clinical trial number NCT04797247 for "Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (LIBerate-CVD)" at ClinicalTrials.gov Clinical trial number NCT04806893 for "Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (LIBerate-HR)" at ClinicalTrials.gov Clinical trial number NCT04797104 for "Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (LIBerate-FH)" at ClinicalTrials.gov
